{"product_id":"anti-human-cannabinoid-receptor-2-extracellular-antibody-bha21300243","title":"Anti-Human Cannabinoid Receptor 2 (extracellular) Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eAnti-Human Cannabinoid Receptor 2 (extracellular) Antibody is an antibody targeting CB2, CNR2 Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in IC, IF, IFC, LCI, WB to detect, localize, or compare expression of the target across samples.\u003c\/p\u003e  \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e CB2, CNR2 (also reported as CB2, CNR2).\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eImmunogen\/epitope region:\u003c\/strong\u003e Extracellular, N-terminus.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eHomology note:\u003c\/strong\u003e Canis, bovine - 10\/14 amino acid residues identical (informative for cross-species interpretation).\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity (as provided):\u003c\/strong\u003e Human.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eSpecificity statement (as provided):\u003c\/strong\u003e Not recommended to use with rat and mouse samples..\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eLot quality control (as provided):\u003c\/strong\u003e Western blot analysis.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003ePeptide confirmation:\u003c\/strong\u003e Confirmed by amino acid analysis and mass spectrometry.\u003c\/li\u003e   \u003cli\u003e\n\u003cstrong\u003eBlocking peptide:\u003c\/strong\u003e Available for antigen preadsorption control where appropriate.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThese attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.\u003c\/p\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eCannabinoids have been used as pain relievers in Eastern medicine for many years.1 To date, two specific cannabinoid receptors have been identified: cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).2 The cannabinoid receptors can be distinguished by their amino acid sequence, signaling mechanisms and tissue distribution.2 Both receptors belong to the G-protein coupled receptor superfamily and are coupled to Gi\/0 G protein.2,3The CB2 is highly expressed in cells of the immune system such as macrophages, lymphocytes natural killer cells and mast cells but has also been shown to be expressed, by both, in situ-hybridization and in immunohistochemistry, in spleen, thymus, and pancreas.1,2,4 CB2 expression in brain is still much less characterized than that of CB1. Recently, it was demonstrated that CB2 is expressed in the brain and might have a role in controlling fundamental processes such as proliferation and survival of neural cells.5,6Overexpression of CB2 was reported in several cancers such as prostate, glioma and acute myeloid leukemias.7-9 In human astrocytoma a direct relation between CB2 expression and tumor malignancy was demonstrated.8 Activation of CB2R in vivo by its agonist JWH-133, completely blocked cell growth.8 In C6 glioma, it was shown that activation of the CB2 by JWH-133 resulted in internalization of only the CB2 and not CB1 leading to apoptosis of the cells. This may well be a new approach for the treatment of glioma.\u003c\/p\u003e  \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003eMapping receptor\/channel localization across neuronal subtypes and subcellular compartments.\u003c\/li\u003e   \u003cli\u003eLinking trafficking or surface expression changes to activity-dependent signaling and plasticity.\u003c\/li\u003e   \u003cli\u003eUsing KO\/KD or blocking-peptide concepts to strengthen antibody-based target assignment.\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003eWestern blot (WB): compare target abundance\/size across lysates and conditions; consider isoforms\/PTMs.\u003c\/li\u003e   \u003cli\u003eImmunofluorescence\/ICC: assess subcellular localization and co-localization with markers in cells or sections.\u003c\/li\u003e   \u003cli\u003eFlow cytometry (direct\/indirect): quantify target-positive populations and shifts in expression across subsets.\u003c\/li\u003e   \u003cli\u003eLive cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO\/KD) and using orthogonal readouts where feasible.\u003c\/p\u003e  \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e   \u003cli\u003eIsoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.\u003c\/li\u003e   \u003cli\u003eCross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.\u003c\/li\u003e   \u003cli\u003ePermeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.\u003c\/li\u003e   \u003cli\u003eConceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.\u003c\/li\u003e   \u003cli\u003eProvided control suggestions: Negative control: BLP-CR003.\u003c\/li\u003e   \u003cli\u003eApplication notes: see product-specific dilution\/usage notes and control concepts provided in the dataset.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cstrong\u003eApplication abbreviations:\u003c\/strong\u003e CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. \u003cstrong\u003eSpecies abbreviations:\u003c\/strong\u003e H- Human, M- Mouse, R- Rat.\u003c\/p\u003e \u003cp\u003e\u003cstrong\u003eRecommended controls:\u003c\/strong\u003e Blocking peptide: BLP-CR003; Negative control: BLP-CR003.\u003c\/p\u003e \u003c!-- Sources (internal): - Alomone Labs product page scientific background (as provided in this catalog row) - UniProt Knowledgebase (target-level reference) - NCBI Gene (target-level reference) - General antibody validation principles (KO\/KD, peptide competition, isotype control concepts) --\u003e","brand":"Alomone Labs","offers":[{"title":"0.2 ml (Carrier Free) \/ 1","offer_id":53064822849901,"sku":"ACR-003-CF-0P2ML-1","price":994.0,"currency_code":"USD","in_stock":true},{"title":"0.2 ml \/ 1","offer_id":53064881930605,"sku":"ACR-003-0P2ML-1","price":795.0,"currency_code":"USD","in_stock":true},{"title":"25 mcl \/ 1","offer_id":53064881963373,"sku":"ACR-003-25MCL-1","price":597.0,"currency_code":"USD","in_stock":true},{"title":"50 mcl \/ 1","offer_id":53064881996141,"sku":"ACR-003-50MCL-1","price":697.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ACR-003_IC_pic.jpg?v=1772460951","url":"https:\/\/www.ebiohippo.com\/products\/anti-human-cannabinoid-receptor-2-extracellular-antibody-bha21300243","provider":"BioHippo","version":"1.0","type":"link"}